-
Prescription Drugs Market Overview:
The global prescription drugs market was valued at US$ 1050.26 Mn in 2021 and is projected to register а САGR of 9.0% by 2031.
Prescription drugs are also called prescription medicine. It is a pharmaceutical drug that requires a legal prescription from a doctor or dentist to dispense. The Prescription drugs are: prescribed by a doctor, bought at a pharmacy, prescribed for and intended to be used by one person, and regulated by FDA through the new drug application (NDA) process.
Prescription medicines help treat many illnesses. Stimulants enable manage attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. Central nervous system (CNS) depressants treat anxiety, panic, and sleep disorders.
There are various types of prescription drugs commercially available on the market, each belonging to a specific drug class. Prescription drugs are helpful for patients suffering from various physical and mental health issues; however, many people abuse them for their desirable effects. The abuse and misuse of medical prescription drugs is a significant problem in the U.S. According to WHO, approximately 54 million Americans have misused prescription medications at least once in their lifetime.
Top 10 Pharmaceutical Companies Prescription Drug Market Share (%) in 2019 (A) & 2026(F)
Global Prescription Drugs Market Revenue Outlook:
Nonetheless, various industry players in the global prescription drugs markets are now increasing their focus towards the establishment of successful collaborations, acquisitions, and joint venture activities as a means to enhance their respective customer bases. In doing so, these players are also increasing their supply capabilities to meet customer requirements on a local and global scale. This factor, paired with promising industrialization prospects in developing economies of the Asia-Pacific region, such as China, India, Taiwan, Indonesia, etc., are expected to create massive business opportunities for key players over the forecast period.
The Top 30 Prescription Drug Information of 2021
Rank Drug Name Total Prescriptions (2018) 1 Atorvastatin 112474023 2 Levothyroxine 105773990 3 Lisinopril 97608879 4 Metformin Hydrochloride 83762981 5 Amlodipine 75811947 6 Metoprolol 71581961 7 Albuterol 60526457 8 Omeprazole 58364556 9 Losartan Potassium 50479750 10 Simvastatin 48007043 11 Gabapentin 45586654 12 Acetaminophen; Hydrocodone Bitartrate 42073176 13 Hydrochlorothiazide 40575075 14 Sertraline Hydrochloride 38383042 15 Montelukast 35222630 16 Fluticasone 34253764 17 Amoxicillin 31371675 18 Furosemide 29857945 19 Pantoprazole Sodium 28958134 20 Acetaminophen 27907360 21 Prednisone 27057494 22 Escitalopram Oxalate 25978773 23 Fluoxetine Hydrochloride 25619277 24 Tramadol Hydrochloride 24952328 25 Insulin Glargine 24911721 26 Bupropion 24488843 27 Ibuprofen 24453501 28 Rosuvastatin 24138061 29 Pravastatin Sodium 24022031 30 Trazodone Hydrochloride 23889624 Increasing Incidence of Chronic Diseases and Conditions to Fuel Demand
Chronic diseases and conditions are increasing globally. According to the WHO, chronic disease prevalence is expected to rise by 57% by 2020. The elderly population and changes in societal behavior are paying for a steady increase in these communal and costly health complications. The middle-class population is growing, and with urbanization accelerating, people are adopting a more sedentary lifestyle. This is pushing obesity rates and cases of diseases such as diabetes upward. The 13 major chronic diseases that are a significant burden in terms of morbidity, mortality and healthcare are cardiovascular disease, stroke, lung cancer, colorectal cancer, depression, type 2 diabetes, arthritis, osteoporosis, asthma, obesity, chronic obstructive pulmonary disease (COPD), chronic kidney disease, and oral disease.
Impact of Pandemic on Healthcare
The pandemics of the past decade have demonstrated the speed at which infections spread across the globe—Covid-19, Ebola, SARS, MERS, and H1N1, the demand for coordinated and agile healthcare responses. Pandemics will, in all likelihood, exert periodic and significant disruptive pressure on health systems. Healthcare organizations across the globe need to be ready to work together to contain outbreaks quickly when they occur.
The Most Prescribed Drugs of 2020
Top Drug Brand Name Indications Amoxicillin 500 mg Amoxil, Trimox Bacterial infections Vitamin D 50,000 IU Drisdol Hypoparathyroidism, osteomalacia, vitamin D deficiency Ibuprofen 800 mg Motrin Pain, inflammation Cetirizine hydrochloride 10 mg Zyrtec Allergy symptoms Azithromycin 250 mg Zithromax Bacterial infections Amlodipine besylate 10 mg Norvasc Chest pain, high blood pressure Albuterol sulfate HFA 90 mcg/act Proventil HFA, Proair HFA, Ventolin HFA Wheezing, shortness of breath caused by breathing problems Cyclobenzaprine hydrochloride 10 mg Flexeril Muscle spasms Cephalexin 500 mg Keflex Bacterial infections Hydrochlorothiazide 25 mg Microzide High blood pressure High Cost of Some Prescription Medicines Hamper Market Growth
High drug costs have increased the financial burden on patients who need access to lifesaving medications and the U.S. health care system. Despite the launch of new and novel medical managements, prescriptions that have been around for years are getting more expensive. The most major reason for the high cost of prescription drugs is the existence of a monopoly.
Some Expensive Drugs in the U.S
Drug name Manufacturer List price (Approx.) Zokinvy* Eiger BioPharmaceuticals $86,040 Myalept Aegerion Pharmaceuticals $74,159 Mavenclad* EMD Serono, Inc. $60,371 Ravicti* Horizon Therapeutics $57,998 Actimmune Horizon Therapeutics $55,310 Oxervate Dompé $48,498 Takhzyro Takeda $46,828 Juxtapid Aegerion Pharmaceuticals $46,502 Cinryze Takeda $45,465 Chenodal* Travere Therapeutics $42,570 Gattex Takeda $41,664 H.P. Acthar Mallinckrodt Pharmaceuticals $39,864 Orladeyo BioCryst Pharmaceuticals $37,308 Tegsedi Akcea Therapeutics $35,638 Ayvakit Blueprint Medicines $33,568 Vitrakvi Bayer Pharmaceuticals $32,800 Qinlock Decipera Pharmaceuticals $32,000 Korlym Corcept Therapeutics $31,440 Cerdelga Genzyme Corporation $28,599 Idhifa Celgene Corporation $28,246 Country-wise Analysis
Why are Prescription Drugs sales higher in the U.S.?
The U.S. market for Prescription Drugs is expected to register a higher share as compared to other regions. The United States alone spends ~ US$ 350 billion. These high spending rates are expected to increase at a rate of 3–6% annually worldwide. The magnitude of the increase is even more alarming for cancer treatments that account for a large proportion of prescription drug costs.
Some Most Common Drugs by Total Prescriptions in the U.S.
- Lisinopril: ~104 Million Prescriptions
The ACE inhibitor is the most prescribed drug in the U.S. It’s used for the treatment of High Bp and heart failure. Sold under brand names such as Prinivil and Zestril.
- Atorvastatin: ~104 Million Prescriptions
It is used to lower low-density lipoprotein (LDL) cholesterol and reduce the risk of heart attack and strokes.
- Levothyroxine: ~101.9 Million Prescriptions
Selling under brand names such as Levo-T, Synthroid, Euthyrox, and Levoxyl.
- Metformin: ~78.6 Million Prescriptions
Drug Class Biguanide – Metformin is a widely prescribed drug for type 2 diabetes. It is sold under the brand - Glumetza, Glucophage, Fortamet, and Riomet.
- Amlodipine: ~ 72.5 Million Prescriptions
They are widely prescribed to treat high blood pressure, chest pain, and coronary artery disease, sold under Brand-name versions including Norvasc, Katerzia, and Amvaz.
- Metoprolol: ~68 Million Prescriptions
Brand prescribing names like Lopresso and Toprol provide. They are used for the treatment of blood pressure and chest pain.
- Omeprazole: ~58.8 Million Prescriptions
Helps in relieving gastrointestinal problems such as reflux, ulcers, heartburn, and IBS
- Losartan: ~52 Million Prescriptions
They are used for the treatment of People with heart conditions & high blood pressure. This prescription is a bit more expensive, though, at an average of $128.90.
Competitive Landscape
The prescription drugs landscape appears highly consolidated, with a major chunk of it being dominated by players.
- Novartis AG
- Pfizer, Inc.
- Hoffmann-La Roche Ltd
- Sanofi
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- AbbVie, Inc.
- GlaxoSmithKline Plc.
- AstraZeneca Plc
- Celgene Corporation
- Other Players
Report Scope
- Forecast Period: 2022-2031
- Actual Year: 2021
- Historical Data Available for: 2015-2020
Key Regions Covered
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Segments Covered
Prescription Drugs Market, By Product Type
- Generics Drugs
- Branded Drugs
- Orphan Drugs
Prescription Drugs Market, By Indications
- Oncology
- Anti-diabetics
- Vaccines
- Sensory Organs
- Immunosuppressants
- Anticoagulants
- Other Indications
Prescription Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn -
- Novartis AG
- Pfizer, Inc.
- Hoffmann-La Roche Ltd
- Sanofi
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- AbbVie, Inc.
- GlaxoSmithKline Plc.
- AstraZeneca Plc
- Celgene Corporation
- Other Players
-
- Chapter 1 Global Prescription Drugs Market Outlook
- 1.1 Introduction
- 1.2 Segmentation of Prescription Drugs Market Based On Product Type, Indications, Distribution Channel and Region
- 1.3 Market Drivers
- 1.4 Market Restraints
- 1.5 Market Opportunities
- 1.6 Market Trends
- 1.7 Macro-economic Factors
- 1.8 Regulatory Framework
- 1.9 Global Prescription Drugs Market Pricing Analysis by Region, 2021
- 1.10 Opportunity Map Analysis
- 1.10.1 Optimistic Scenario
- 1.10.2 Likely Scenario
- 1.10.3 Conservative Scenario
- 1.11 Opportunity Orbits
- 1.12 Market Investment Feasibility Index
- 1.13 PEST Analysis
- 1.14 PORTER’S Five Force Analysis
- 1.15 Drivers & Restraints Impact Analysis
- 1.16 Marketing Strategy
- 1.17 Product Life Cycle Analysis
- 1.18 Value Chain Analysis
- 1.19 Cost Structure Analysis
- 1.20 Regional Market Share and BPS Analysis in Prescription Drugs Market
- 1.21 COVID-19 Impact Analysis
- Chapter 2 Global Prescription Drugs Market Overview
- 2.1 Global Market Value & Volume Comparison by Product Type (2015-2031)
- 2.1.1 Global Market Value & Volume Market Share by Product Type in 2021
- 2.1.2 Global Market Attractiveness Analysis by Product Type, 2015–2022
- 2.2 Global Market Value & Volume Comparison by Indications (2015-2031)
- 2.2.1 Global Market Value & Volume Market Share by Indications in 2021
- 2.2.2 Global Market Attractiveness Analysis by Indications, 2015–2022
- 2.3 Global Market by Distribution Channel
- 2.3.1 Global Market Value & Volume Comparison by Distribution Channel (2015-2031)
- 2.3.2 Global Market Value & Volume Market Share by Distribution Channel in 2021
- 2.3.3 Global Market Attractiveness Analysis by Distribution Channel, 2015–2022
- 2.4 Global Market Outlook by Region
- 2.4.1 Global Market Value & Volume Comparison by Region (2015-2031)
- 2.4.2 Global Market Value & Volume Market Share by Region in 2021
- 2.4.3 Global Market Attractiveness Analysis by Region, 2015–2022
- 2.5 Global Market Outlook (2015-2031)
- 2.5.1 Global Market Value & Volume (2015–2022)
- 2.5.2 Global Market Value & Volume (2023-2031)
- 2.6 Global Market Value & Volume by Regions
- 2.6.1 Global Market Value & Volume Comparison by Region (2015–2022)
- 2.6.2 Global Market Value & Volume Comparison by Region (2023-2031)
- 2.7 Global Market Value & Volume by Product Type
- 2.7.1 Global Market Value & Volume Comparison by Product Type (2015–2022)
- 2.7.2 Global Market Value & Volume Comparison by Product Type (2023-2031)
- 2.8 Global Market Value & Volume by Indications
- 2.8.1 Global Market Value & Volume Comparison by Indications (2015–2022)
- 2.8.2 Global Market Value & Volume Comparison by Indications (2023-2031)
- 2.9 Global Market Value & Volume by Distribution Channel
- 2.9.1 Global Market Value & Volume Comparison by Distribution Channel (2015–2022)
- 2.9.2 Global Market Value & Volume Comparison by Distribution Channel (2023-2031)
- 2.10 Global Market Y-o-Y Growth Rate Comparison 2016–2031
- 2.10.1 Global Market Y-o-Y Growth Rate by Region
- 2.10.2 Global Market Y-o-Y Growth Rate by Product Type
- 2.10.3 Global Market Y-o-Y Growth Rate by Indications
- 2.10.4 Global Market Y-o-Y Growth Rate by Distribution Channel
- 2.11 Global Market Share Comparison 2015–2030
- 2.11.1 Global Market Share by Region
- 2.11.2 Global Market Share by Product Type
- 2.11.3 Global Market Share by Indications
- 2.11.4 Global Market Share by Distribution Channel
- 2.1 Global Market Value & Volume Comparison by Product Type (2015-2031)
- Chapter 3 North America Prescription Drugs Market Overview
- 3.1 North America Market by Product Type
- 3.1.1 North America Market Value & Volume Comparison by Product Type (2015-2031)
- 3.1.2 North America Market Value & Volume Market Share by Product Type in 2021
- 3.2 North America Market Value & Volume Comparison by Indications (2015-2031)
- 3.2.1 North America Market Value & Volume Market Share by Indications in 2021
- 3.2.2 North America Market Attractiveness Analysis by Indications, 2015–2022
- 3.3 North America Market by Distribution Channel
- 3.3.1 North America Market Value & Volume Comparison by Distribution Channel (2015-2031)
- 3.3.2 North America Market Value & Volume Market Share by Distribution Channel in 2021
- 3.3.3 North America Market Attractiveness Analysis by Distribution Channel, 2015–2022
- 3.4 North America Market Outlook by Region
- 3.4.1 North America Market Value & Volume Comparison by Region (2015-2031)
- 3.4.2 North America Market Value & Volume Market Share by Region in 2021
- 3.4.3 North America Market Attractiveness Analysis by Region, 2015–2022
- 3.5 North America Market Outlook (2015-2031)
- 3.5.1 North America Market Value & Volume (2015–2022)
- 3.5.2 North America Market Value & Volume (2023-2031)
- 3.6 North America Market Value & Volume by Regions
- 3.6.1 North America Market Value & Volume Comparison by Region (2015–2022)
- 3.6.2 North America Market Value & Volume Comparison by Region (2023-2031)
- 3.7 North America Market Value & Volume by Product Type
- 3.7.1 North America Market Value & Volume Comparison by Product Type (2015–2022)
- 3.7.2 North America Market Value & Volume Comparison by Product Type (2023-2031)
- 3.8 North America Market Value & Volume by Indications
- 3.8.1 North America Market Value & Volume Comparison by Indications (2015–2022)
- 3.8.2 North America Market Value & Volume Comparison by Indications (2023-2031)
- 3.9 North America Market Value & Volume by Distribution Channel
- 3.9.1 North America Market Value & Volume Comparison by Distribution Channel (2015–2022)
- 3.9.2 North America Market Value & Volume Comparison by Distribution Channel (2023-2031)
- 3.10 North America Market Y-o-Y Growth Rate Comparison 2016–2031
- 3.10.1 North America Market Y-o-Y Growth Rate by Region
- 3.10.2 North America Market Y-o-Y Growth Rate by Product Type
- 3.10.3 North America Market Y-o-Y Growth Rate by Indications
- 3.10.4 North America Market Y-o-Y Growth Rate by Distribution Channel
- 3.11 North America Market Share Comparison 2015–2030
- 2.11.1 North America Market Share by Region
- 3.11.2 North America Market Share by Product Type
- 3.11.3 North America Market Share by Indications
- 3.11.4 North America Market Share by Distribution Channel
- 3.1 North America Market by Product Type
- Chapter 4 Europe Prescription Drugs Market Overview
- 4.1 Europe Market by Product Type
- 4.1.1 Europe Market Value & Volume Comparison by Product Type (2015-2031)
- 4.1.2 Europe Market Value & Volume Market Share by Product Type in 2021
- 4.2 Europe Market Value & Volume Comparison by Indications (2015-2031)
- 4.2.1 Europe Market Value & Volume Market Share by Indications in 2021
- 4.2.2 Europe Market Attractiveness Analysis by Indications, 2015–2022
- 4.3 Europe Market by Distribution Channel
- 4.3.1 Europe Market Value & Volume Comparison by Distribution Channel (2015-2031)
- 4.3.2 Europe Market Value & Volume Market Share by Distribution Channel in 2021
- 4.3.3 Europe Market Attractiveness Analysis by Distribution Channel, 2015–2022
- 4.4 Europe Market Outlook by Region
- 4.4.1 Europe Market Value & Volume Comparison by Region (2015-2031)
- 4.4.2 Europe Market Value & Volume Market Share by Region in 2021
- 4.4.3 Europe Market Attractiveness Analysis by Region, 2015–2022
- 4.5 Europe Market Outlook (2015-2031)
- 4.5.1 Europe Market Value & Volume (2015–2022)
- 4.5.2 Europe Market Value & Volume (2023-2031)
- 4.6 Europe Market Value & Volume by Regions
- 4.6.1 Europe Market Value & Volume Comparison by Region (2015–2022)
- 4.6.2 Europe Market Value & Volume Comparison by Region (2023-2031)
- 4.7 Europe Market Value & Volume by Product Type
- 4.7.1 Europe Market Value & Volume Comparison by Product Type (2015–2022)
- 4.7.2 Europe Market Value & Volume Comparison by Product Type (2023-2031)
- 4.8 Europe Market Value & Volume by Indications
- 4.8.1 Europe Market Value & Volume Comparison by Indications (2015–2022)
- 4.8.2 Europe Market Value & Volume Comparison by Indications (2023-2031)
- 4.9 Europe Market Value & Volume by Distribution Channel
- 4.9.1 Europe Market Value & Volume Comparison by Distribution Channel (2015–2022)
- 4.9.2 Europe Market Value & Volume Comparison by Distribution Channel (2023-2031)
- 4.9 Europe Market Y-o-Y Growth Rate Comparison 2016–2031
- 4.10.1 Europe Market Y-o-Y Growth Rate by Region
- 4.10.2 Europe Market Y-o-Y Growth Rate by Product Type
- 4.10.3 Europe Market Y-o-Y Growth Rate by Indications
- 4.10.4 Europe Market Y-o-Y Growth Rate by Distribution Channel
- 4.11 Europe Market Share Comparison 2015–2030
- 4.11.1 Europe Market Share by Region
- 4.11.2 Europe Market Share by Product Type
- 4.11.3 Europe Market Share by Indications
- 4.11.4 Europe Market Share by Distribution Channel
- 4.1 Europe Market by Product Type
- Chapter 5 Asia-Pacific Prescription Drugs Market Overview
- 5.1 Asia-Pacific Market by Product Type
- 5.1.1 Asia-Pacific Market Value & Volume Comparison by Product Type (2015-2031)
- 5.1.2 Asia-Pacific Market Value & Volume Market Share by Product Type in 2021
- 5.2 Asia-Pacific Market Value & Volume Comparison by Indications (2015-2031)
- 5.2.1 Asia-Pacific Market Value & Volume Market Share by Indications in 2021
- 5.2.2 Asia-Pacific Market Attractiveness Analysis by Indications, 2015–2022
- 5.3 Asia-Pacific Market by Distribution Channel
- 5.3.1 Asia-Pacific Market Value & Volume Comparison by Distribution Channel (2015-2031)
- 5.3.2 Asia-Pacific Market Value & Volume Market Share by Distribution Channel in 2021
- 5.3.3 Asia-Pacific Market Attractiveness Analysis by Distribution Channel, 2015–2022
- 5.4 Asia-Pacific Market Outlook by Region
- 5.4.1 Asia-Pacific Market Value & Volume Comparison by Region (2015-2031)
- 5.4.2 Asia-Pacific Market Value & Volume Market Share by Region in 2021
- 5.4.3 Asia-Pacific Market Attractiveness Analysis by Region, 2015–2022
- 5.5 Asia-Pacific Market Outlook (2015-2031)
- 5.5.1 Asia-Pacific Market Value & Volume (2015–2022)
- 5.5.2 Asia-Pacific Market Value & Volume (2023-2031)
- 5.6 Asia-Pacific Market Value & Volume by Regions
- 5.6.1 Asia-Pacific Market Value & Volume Comparison by Region (2015–2022)
- 5.6.2 Asia-Pacific Market Value & Volume Comparison by Region (2023-2031)
- 5.7 Asia-Pacific Market Value & Volume by Product Type
- 5.7.1 Asia-Pacific Market Value & Volume Comparison by Product Type (2015–2022)
- 5.7.2 Asia-Pacific Market Value & Volume Comparison by Product Type (2023-2031)
- 5.8 Asia-Pacific Market Value & Volume by Indications
- 5.8.1 Asia-Pacific Market Value & Volume Comparison by Indications (2015–2022)
- 5.8.2 Asia-Pacific Market Value & Volume Comparison by Indications (2023-2031)
- 5.9 Asia-Pacific Market Value & Volume by Distribution Channel
- 5.9.1 Asia-Pacific Market Value & Volume Comparison by Distribution Channel (2015–2022)
- 5.9.2 Asia-Pacific Market Value & Volume Comparison by Distribution Channel (2023-2031)
- 5.10 Asia-Pacific Market Y-o-Y Growth Rate Comparison 2016–2031
- 5.10.1 Asia-Pacific Market Y-o-Y Growth Rate by Region
- 5.10.2 Asia-Pacific Market Y-o-Y Growth Rate by Product Type
- 5.10.3 Asia-Pacific Market Y-o-Y Growth Rate by Indications
- 5.10.4 Asia-Pacific Market Y-o-Y Growth Rate by Distribution Channel
- 5.11 Asia-Pacific Market Share Comparison 2015–2030
- 5.11.1 Asia-Pacific Market Share by Region
- 5.11.2 Asia-Pacific Market Share by Product Type
- 5.11.3 Asia-Pacific Market Share by Indications
- 5.11.4 Asia-Pacific Market Share by Distribution Channel
- 5.1 Asia-Pacific Market by Product Type
- Chapter 6 Latin America Prescription Drugs Market Overview
- 6.1 Latin America Market by Product Type
- 6.1.1 Latin America Market Value & Volume Comparison by Product Type (2015-2031)
- 6.1.2 Latin America Market Value & Volume Market Share by Product Type in 2021
- 6.2 Latin America Market Value & Volume Comparison by Indications (2015-2031)
- 6.2.1 Latin America Market Value & Volume Market Share by Indications in 2021
- 6.2.2 Latin America Market Attractiveness Analysis by Indications, 2015–2022
- 6.3 Latin America Market by Distribution Channel
- 6.3.1 Latin America Market Value & Volume Comparison by Distribution Channel (2015-2031)
- 6.3.2 Latin America Market Value & Volume Market Share by Distribution Channel in 2021
- 6.3.3 Latin America Market Attractiveness Analysis by Distribution Channel, 2015–2022
- 6.4 Latin America Market Outlook by Region
- 6.4.1 Latin America Market Value & Volume Comparison by Region (2015-2031)
- 6.4.2 Latin America Market Value & Volume Market Share by Region in 2021
- 6.4.3 Latin America Market Attractiveness Analysis by Region, 2015–2022
- 6.5 Latin America Market Outlook (2015-2031)
- 6.5.1 Latin America Market Value & Volume (2015–2022)
- 6.5.2 Latin America Market Value & Volume (2023-2031)
- 6.6 Latin America Market Value & Volume by Regions
- 6.6.1 Latin America Market Value & Volume Comparison by Region (2015–2022)
- 6.6.2 Latin America Market Value & Volume Comparison by Region (2023-2031)
- 6.7 Latin America Market Value & Volume by Product Type
- 6.7.1 Latin America Market Value & Volume Comparison by Product Type (2015–2022)
- 6.7.2 Latin America Market Value & Volume Comparison by Product Type (2023-2031)
- 6.8 Latin America Market Value & Volume by Indications
- 6.8.1 Latin America Market Value & Volume Comparison by Indications (2015–2022)
- 6.8.2 Latin America Market Value & Volume Comparison by Indications (2023-2031)
- 6.9 Latin America Market Value & Volume by Distribution Channel
- 6.9.1 Latin America Market Value & Volume Comparison by Distribution Channel (2015–2022)
- 6.9.2 Latin America Market Value & Volume Comparison by Distribution Channel (2023-2031)
- 6.10 Latin America Market Y-o-Y Growth Rate Comparison 2016–2031
- 6.10.1 Latin America Market Y-o-Y Growth Rate by Region
- 6.10.2 Latin America Market Y-o-Y Growth Rate by Product Type
- 6.10.3 Latin America Market Y-o-Y Growth Rate by Indications
- 6.10.4 Latin America Market Y-o-Y Growth Rate by Distribution Channel
- 6.11 Latin America Market Share Comparison 2015–2030
- 6.11.1 Latin America Market Share by Region
- 6.11.2 Latin America Market Share by Product Type
- 6.11.3 Latin America Market Share by Indications
- 6.11.4 Latin America Market Share by Distribution Channel
- 6.1 Latin America Market by Product Type
- Chapter 7 MEA Prescription Drugs Market Overview
- 7.1 MEA Market by Product Type
- 7.1.1 MEA Market Value & Volume Comparison by Product Type (2015-2031)
- 7.1.2 MEA Market Value & Volume Market Share by Product Type in 2021
- 7.2 MEA Market Value & Volume Comparison by Indications (2015-2031)
- 7.2.1 MEA Market Value & Volume Market Share by Indications in 2021
- 7.2.2 MEA Market Attractiveness Analysis by Indications, 2015–2022
- 7.3 MEA Market by Distribution Channel
- 7.3.1 MEA Market Value & Volume Comparison by Distribution Channel (2015-2031)
- 7.3.2 MEA Market Value & Volume Market Share by Distribution Channel in 2021
- 7.3.3 MEA Market Attractiveness Analysis by Distribution Channel, 2015–2022
- 7.4 MEA Market Outlook by Region
- 7.4.1 MEA Market Value & Volume Comparison by Region (2015-2031)
- 7.4.2 MEA Market Value & Volume Market Share by Region in 2021
- 7.4.3 MEA Market Attractiveness Analysis by Region, 2015–2022
- 7.5 MEA Market Outlook (2015-2031)
- 7.5.1 MEA Market Value & Volume (2015–2022)
- 7.5.2 MEA Market Value & Volume (2023-2031)
- 7.5 MEA Market Value & Volume by Regions
- 7.6.1 MEA Market Value & Volume Comparison by Region (2015–2022)
- 7.6.2 MEA Market Value & Volume Comparison by Region (2023-2031)
- 7.7 MEA Market Value & Volume by Product Type
- 7.7.1 MEA Market Value & Volume Comparison by Product Type (2015–2022)
- 7.7.2 MEA Market Value & Volume Comparison by Product Type (2023-2031)
- 7.8 MEA Market Value & Volume by Indications
- 7.8.1 MEA Market Value & Volume Comparison by Indications (2015–2022)
- 7.8.2 MEA Market Value & Volume Comparison by Indications (2023-2031)
- 7.9 MEA Market Value & Volume by Distribution Channel
- 7.9.1 MEA Market Value & Volume Comparison by Distribution Channel (2015–2022)
- 7.9.2 MEA Market Value & Volume Comparison by Distribution Channel (2023-2031)
- 7.10 MEA Market Y-o-Y Growth Rate Comparison 2016–2031
- 7.10.1 MEA Market Y-o-Y Growth Rate by Region
- 7.10.2 MEA Market Y-o-Y Growth Rate by Product Type
- 7.10.3 MEA Market Y-o-Y Growth Rate by Indications
- 7.10.4 MEA Market Y-o-Y Growth Rate by Distribution Channel
- 7.11 MEA Market Share Comparison 2015–2030
- 7.11.1 MEA Market Share by Region
- 7.11.2 MEA Market Share by Product Type
- 7.11.3 MEA Market Share by Indications
- 7.11.4 MEA Market Share by Distribution Channel
- 7.1 MEA Market by Product Type
- Chapter 8 Global Prescription Drugs Market Company Profiles
- 8.1 Market Competition Scenario Analysis, By Company
- 8.2 Competitor Landscape
- 8.3 Company Share Analysis
- 8.4 Company Profiles
- 8.4.1 Novartis AG
- 8.4.1.1 Company Overview
- 8.4.1.2 Business Description
- 8.4.1.3 Product Portfolio
- 8.4.1.4 Key Financials
- 8.4.1.5 Key Developments
- 8.4.1.6 SWOT Analysis
- 8.4.2 Pfizer, Inc.
- 8.4.2.1 Company Overview
- 8.4.2.2 Business Description
- 8.4.2.3 Product Portfolio
- 8.4.2.4 Key Financials
- 8.4.2.5 Key Developments
- 8.4.2.6 SWOT Analysis
- 8.4.3 F. Hoffmann-La Roche Ltd
- 8.4.3.1 Company Overview
- 8.4.3.2 Business Description
- 8.4.3.3 Product Portfolio
- 8.4.3.4 Key Financials
- 8.4.3.5 Key Developments
- 8.4.3.6 SWOT Analysis
- 8.4.4 Sanofi
- 8.4.4.1 Company Overview
- 8.4.4.2 Business Description
- 8.4.4.3 Product Portfolio
- 8.4.4.4 Key Financials
- 8.4.4.5 Key Developments
- 8.4.4.6 SWOT Analysis
- 8.4.5 Johnson & Johnson Services, Inc.
- 8.4.5.1 Company Overview
- 8.4.5.2 Business Description
- 8.4.5.3 Product Portfolio
- 8.4.5.4 Key Financials
- 8.4.5.5 Key Developments
- 8.4.5.6 SWOT Analysis
- 8.4.6 Merck & Co., Inc.
- 8.4.6.1 Company Overview
- 8.4.6.2 Business Description
- 8.4.6.3 Product Portfolio
- 8.4.6.4 Key Financials
- 8.4.6.5 Key Developments
- 8.4.6.6 SWOT Analysis
- 8.4.7 AbbVie, Inc.
- 8.4.7.1 Company Overview
- 8.4.7.2 Business Description
- 8.4.7.3 Product Portfolio
- 8.4.7.4 Key Financials
- 8.4.7.5 Key Developments
- 8.4.7.6 SWOT Analysis
- 8.4.8 GlaxoSmithKline Plc.
- 8.4.8.1 Company Overview
- 8.4.8.2 Business Description
- 8.4.8.3 Product Portfolio
- 8.4.8.4 Key Financials
- 8.4.8.5 Key Developments
- 8.4.8.6 SWOT Analysis
- 8.4.9 AstraZeneca Plc
- 8.4.9.1 Company Overview
- 8.4.9.2 Business Description
- 8.4.9.3 Product Portfolio
- 8.4.9.4 Key Financials
- 8.4.9.5 Key Developments
- 8.4.9.6 SWOT Analysis
- 8.4.10 Celgene Corporation
- 8.4.10.1 Company Overview
- 8.4.10.2 Business Description
- 8.4.10.3 Product Portfolio
- 8.4.10.4 Key Financials
- 8.4.10.5 Key Developments
- 8.4.10.6 SWOT Analysis
- 8.4.11 Other Key Players
- 8.4.1 Novartis AG
- Chapter 9 Research Methodology
- 9.1 Research Methodology
- 9.2 Primary Research
- 9.3 Secondary Research
- 9.4 Report Scope
- Chapter 10 About Us
- 10.1 Who we are:
- Chapter 11 Disclaimer
- Chapter 1 Global Prescription Drugs Market Outlook
-
Inquiry Form
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
-
Request for Customization
OUR CLIENTS
Don't just take our word. We are trusted by these great companies!